Would you provide abemaciclib to a premenopausal women with cT2 cN1 ER+ breast cancer and Ki67 of 80% who achieves pCR following neoadjuvant AC-T?

Topics: Breast Cancer • Medical Oncology • Breast Cancer, Non-metastatic

What would you offer a premenopausal woman with clinical T2N1 ER positive breast cancer for adjuvant therapy after she achieves a pathologic complete response to neoadjuvant AC-T? She meets the criteria for high risk disease per MonarchE given positive node + Ki67 of 80%.

Answer from: Medical Oncologist at Community Practice

Patients who received neoadjuvant Chemotherapy were only eligible for the trial if they had residual disease above a threshold quantified using CPS-EG.

Comments

Medical Oncologist at University of Pittsburgh Medical Center
Thank you. I was not able to find information on r...

Medical Oncologist at Fort Sutter Med Onc/Hem
I’m sorry, I was wrong about that. CPS EG wa...

Related Questions